×
About 1,768 results

ALLMedicine™ Biliary Tract Cancer Center

Research & Reviews  582 results

Sarcopenia Predicts Relevant Clinical Outcomes in Biliary Tract Cancer Patients: A Syst...
https://doi.org/10.1080/01635581.2022.2074063
Nutrition and Cancer; Yang L, He Y et. al.

May 12th, 2022 - The purpose of this meta-analysis was to analyze the influences of sarcopenia on clinical outcomes in patients with biliary tract cancer (BTC). A systematic literature search was performed in November 2021. Some studies that reported the impacts o...

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
https://clinicaltrials.gov/ct2/show/NCT04482309

May 11th, 2022 - This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will enroll 7 tumor-specific cohorts: urothelia...

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Col...
https://clinicaltrials.gov/ct2/show/NCT03929666

May 11th, 2022 - Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus standard first-line combination chemotherapy (XELOX, FP, or mFOLFOX6 for GEA; mFOLFOX6 with or without bevacizumab for CRC; and CisGem for BTC) and will confirm the r...

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
https://clinicaltrials.gov/ct2/show/NCT04579380

May 10th, 2022 - There are multiple cohorts in this trial: 5 tumor specific cohorts with HER2 overexpression/amplification (cervical cancer, uterine cancer, biliary tract cancer, urothelial cancer, and non-squamous non-small cell lung cancer [NSCLC]) 2 tumor speci...

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
https://clinicaltrials.gov/ct2/show/NCT04042831

May 9th, 2022 - PRIMARY OBJECTIVES: I. To determine the efficacy (objective response rate) of olaparib monotherapy in advanced biliary tract cancer (BTC) with mutations in deoxyribonucleic acid (DNA) repair genes. SECONDARY OBJECTIVES: I. To determine the overall...

see more →

Guidelines  2 results

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058005
Clinical & Translational Oncology : Official Publication ... Gómez-España MA, Montes AF et. al.

Mar 5th, 2021 - Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. Surgery i...

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.
https://doi.org/10.1200/JCO.18.02178
Journal of Clinical Oncology : Official Journal of the Am... Shroff RT, Kennedy EB et. al.

Mar 12th, 2019 - To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for ...

see more →

Clinicaltrials.gov  62 results

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
https://clinicaltrials.gov/ct2/show/NCT04482309

May 11th, 2022 - This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will enroll 7 tumor-specific cohorts: urothelia...

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Col...
https://clinicaltrials.gov/ct2/show/NCT03929666

May 11th, 2022 - Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus standard first-line combination chemotherapy (XELOX, FP, or mFOLFOX6 for GEA; mFOLFOX6 with or without bevacizumab for CRC; and CisGem for BTC) and will confirm the r...

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
https://clinicaltrials.gov/ct2/show/NCT04579380

May 10th, 2022 - There are multiple cohorts in this trial: 5 tumor specific cohorts with HER2 overexpression/amplification (cervical cancer, uterine cancer, biliary tract cancer, urothelial cancer, and non-squamous non-small cell lung cancer [NSCLC]) 2 tumor speci...

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
https://clinicaltrials.gov/ct2/show/NCT04042831

May 9th, 2022 - PRIMARY OBJECTIVES: I. To determine the efficacy (objective response rate) of olaparib monotherapy in advanced biliary tract cancer (BTC) with mutations in deoxyribonucleic acid (DNA) repair genes. SECONDARY OBJECTIVES: I. To determine the overall...

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
https://clinicaltrials.gov/ct2/show/NCT05109442

May 3rd, 2022 - There will be 2 parts in this study: a dose escalation phase (phase 1) and an expansion phase (phase 2a). Patients will qualify to receive the investigational drugs (AFM24 + atezolizumab) in the dose escalation phase or the expansion phase only if...

see more →

News  61 results

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

Shelf Life for Accelerated Approvals; CRC Tall Tale; Survivorship: Who's in Charge?
https://www.medpagetoday.com/hematologyoncology/othercancers/97627

Mar 11th, 2022 - Legislation introduced by Rep. Frank Pallone (D-N.J.) would give the FDA authority to set an expiration date on accelerated approvals. (Regulatory Affairs Professionals Society) Immune checkpoint inhibitors developed in China will have to overcome...

Phase 3 NuTide:121 Study Examining NUC-1031 in Biliary Tract Cancer to be Discontinued
https://www.onclive.com/view/phase-3-nutide-121-study-examining-nuc-1031-in-biliary-tract-cancer-to-be-discontinued

Mar 8th, 2022 - The phase 3 NuTide:121 trial (NCT04163900) examining the first-in-class nucleotide analogue NUC-1031 (Acelarin) in combination with cisplatin vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer is being discontinued, accor...

Sequencing Strategies May Shift With Emerging Options in GI Malignancies
https://www.onclive.com/view/sequencing-strategies-may-shift-with-emerging-options-in-gi-malignancies

Feb 11th, 2022 - With the rapid uptake oof novel therapies, shifts in treatment strategies are anticipated in gastrointestinal (GI) malignancies, including hepatobiliary cancers, locally advanced and metastatic pancreatic cancer, gastric/gastroesophageal junction ...

Potential New Standard of Care for Biliary Tract Cancer
https://www.medscape.com/viewarticle/967102

Jan 24th, 2022 - SAN FRANCISCO ― Adding the checkpoint inhibitor durvalumab (Imfinzi) to chemotherapy significantly improved overall survival in patients with advanced biliary tract cancer, as compared to chemotherapy alone, according to interim results from the T...

see more →